BRCA – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of BRCA comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of BRCA for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s BRCA forecast will answer the following questions:
- Of all people with BRCA, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BRCA over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 33 BRCA patient populations, including the following:
- Diagnosed incident cases of BRCA-mutated ovarian cancer.
- Diagnosed incident cases of advanced BRCA-mutated ovarian cancer.
- Recurrent cases of BRCA-mutated exocrine pancreatic cancer.
- Diagnosed first-line drug-treatable BRCA-mutated exocrine pancreatic cancer.
- Diagnosed incident cases of resectable BRCA-mutated exocrine pancreatic cancer.
- Diagnosed incident cases of metastatic non-triple-negative BRCA-mutated breast cancer.
- Diagnosed incident cases of metastatic BRCA-mutated prostate cancer.
- Diagnosed incident cases of triple-negative BRCA-mutated breast cancer.
- Diagnosed first-line drug-treatable BRCA-mutated prostate cancer.
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
- BRCA - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of BRCA)
- Diagnosed incident cases of BRCA-mutated disease
- Diagnosed incident cases of BRCA-mutated breast cancer
- Diagnosed incident cases of BRCA-mutated ovarian cancer
- Diagnosed incident cases of BRCA-mutated pancreatic cancer
- Diagnosed incident cases of BRCA-mutated prostate cancer
- First-line drug-treatable cases of BRCA-mutated breast, ovarian, pancreatic, and prostate cancers
- First-line drug-treatable cases of BRCA-mutated breast cancer
- First-line drug-treatable cases of BRCA-mutated ovarian cancer
- First-line drug-treatable cases of BRCA-mutated pancreatic cancer
- First-line drug-treatable cases of BRCA-mutated prostate cancer
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviation table
Mohani Latwal, B.P.T., M.P.H., is an associate epidemiologist at Clarivate. She received her bachelor’s degree in physiotherapy from Delhi University and her master’s degree in public health with a specialization in social epidemiology from the Tata Institute of Social Sciences in Mumbai. Prior to joining Clarivate, she worked as a deputy manager at an NGO.
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.